Kevin Litchfield, PhD, University College London, London, UK, explains the aims of the TRACERx study, including understanding the basis of tumor heterogeneity and investigating the evolution of microbial cells in the tumor microenvironment. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.